For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

DRL also faces headwinds because of increasing competitive intensity in the generic market and exchange rate volatility.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not cost-effective at current pricing, new research shows.

For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, ...

In a notable move, Hims & Hers Health donated $1 million to President-elect Donald Trump’s inauguration fund, signaling its ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

At her Thanksgiving table in 2024, half of Ashley Dunham's guests were on a GLP-1 weight loss drug. She made green beans for ...

Weight management platform Found is today launching oral semaglutide dissolvable tablets for individuals looking for ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...